Abstract
Background and Objectives Isolated Rapid Eye Movement (REM) sleep behavior disorder (iRBD) is a sleep disorder associated with neurodegenerative diseases such as Parkinson’s disease and dementia with Lewy bodies. Predicting which iRBD patients will phenoconvert to neurodegenerative diseases is crucial for prognosis and management. The objective of this study is to develop a machine learning model using clinical markers to predict phenoconversion in patients with RBD.
Methods Analyzing a cohort of 178 iRBD patients over a median follow-up period of 3.6 years, during which 30 patients converted to neurodegenerative conditions, we leveraged an comprehensive dataset encompassing demographics, medication history, cognitive assessments, sleep quality, autonomic symptoms, and parkinsonian signs. We explored a variety of feature selection methods and survival models. Additionally, separate models to predict the subtype of photoconversion—whether motor-first or cognition-first—were developed.
Results The extreme gradient boosting survival embeddings-Kaplan neighbors (XGBSE-KN) model demonstrated the best performance, achieving a concordance index of 0.823 and integrated Brier score of 0.123 on 10-fold cross-validation. Explainable AI methods provided insights into prediction rationales and key risk factors including age, RBDQ-KR factor 2 (behavioral factors), weight, antidepressant, coffee use, and UPDRS III excluding tremor score. For subtype classification, the RandomForestClassifier utilizing three features (PSQI-TST, MoCA, and age), emerged as the most effective, achieving a Matthews Correlation Coefficient of 0.697 in 100 repeated 5-fold cross-validations. These models have been deployed on a server for physician access.
Discussion These models can aid prognosis and enable personalized management in RBD patients, potentially improving patient care and outcomes. While these findings are promising, further external validation of the models is necessary to confirm their efficacy and reliability in clinical settings. Future research should focus on incorporating additional biomarkers and exploring the models’ performance in larger, diverse cohorts.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Brain Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2017M3C7A1029688) and the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (2017R1A2B2012280).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Board of Seoul National University Hospital (IRB No.: 1708-169-883).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
